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Abstract
The aim of this study was to elucidate the oxidation products of a candidate
antimalarial drug, PL69, using a porphyrin system and to determine the accuracy of the
oxidation products produced, as compared to what is expected in metabolism. PL69 is a
reversed chloroquine (RCQ) that is active against chloroquine resistant malaria.
Porphyrin oxidation systems have been shown to mimic in vitro enzymatic metabolism
reactions. PL69 and its known metabolite, PL16, were incubated with the porphyrin
system, and then the oxidation products were collected and separated by HPLC. The
oxidation products were characterized by NMR and mass spectrometry and compared
to previous metabolism studies of PL69 with liver microsomes. The results of this
research show that this porphyrin system is an acceptable mimic of in vitro metabolism
methods for RCQs and provides a good framework for understanding the types of
metabolism that will occur in vivo for RCQs.
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Introduction
Malaria is a significant issue throughout the world, affecting the lives of many
people. In 2012, 207 million people were infected with malaria, and 627,000 of those
infections resulted in death. Sub-Saharan Africa is the region most affected by malaria,
accounting for 90% of the deaths related to malaria (“10 Facts on Malaria”, 2014). The
physical effects of malaria include fevers, headaches, vomiting, disruption of blood
supply, and, possibly, death (Malaria, 2014). Malaria affects a person physically, but in
endemic areas, also severely affects the country’s economy due to debilitating cyclic
effects during infection, rendering a person unable to work consistently (Gallup, 2001).
Human malaria is caused by five different species of Plasmodiae; Plasmodium ovale,
malariae, knowlesi, vivax, and falciparum. P. falciparum accounts for 95% of deaths
caused by malaria, and is therefore the most heavily researched (Roepe, 2009).
The malaria parasite is transmitted via the female Anopheles mosquito. When
the mosquito takes a blood meal, sporozoites are injected from the mosquito into the
host and go straight to the liver cells to multiply (Figure 1, #1-2). These sporozoites then
invade the host erythrocytes and go through a process of reproduction called
schizogony, producing merozoites (Figure 1, #3-4). The production of many merozoites
then bursts the red blood cells allowing the merozoites to infect other erythrocytes.
Merozoites that infect erythrocytes can differentiate into male and female gametocytes
which can then be taken up by a mosquito (Figure 1, #5-6). Sexual reproduction occurs
1

in the mosquito forming more sporozoites to be transmitted to other hosts (Figure 1,
#7-9) (Sherman, 2005).

Figure 1: The life cycle of the Plasmodium parasite (Klein, 2013)

A common method of treating malaria is to inhibit Plasmodium at the merozoite
stage to prevent rupturing of the erythrocytes, so the merozoites cannot further infect
more erythrocytes. The parasites in the red blood cells digest hemoglobin in their
digestive vacuole (DV) to obtain needed amino acids, releasing free heme
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(ferriprotoporphyrin IX) (Pishchany, 2012). Heme is toxic to the parasite because it does
not have the heme oxygenase pathway, so it forms hemozoin (Roepe, 2009). Hemozoin
is crystallized heme that forms in the digestive vacuole of the parasite because the pH of
the digestive vacuole is about 5.2 and heme precipitates as hemozoin below pH 5.4
(Kuhn, 2007). As it crystallizes, hemozoin deposits in the gut of the parasite, which is
the cause of the characteristic black granules in erythrocytes infected with malaria.
Rupturing of the red blood cells releases the merozoites as well as hemozoin. This stage
of the Plasmodium lifecycle is what causes the symptoms commonly associated with
malaria.
Inhibiting formation of hemozoin has been a target for many antimalarial drug
therapies, and is the method of action for one of the most widely known and used
antimalarial drugs, chloroquine (CQ) (Figure 2). CQ was put in to use shortly after WWII
and was very successful because it was effective, inexpensive, and safe for children and
pregnant women (Wellems, 2001). CQ is active against P. falciparum through
interactions with heme in the digestive vacuole of the parasite. There is a large
accumulation of CQ in the digestive vacuole in part because of a pH gradient between
the cytoplasm of the red blood cells, the cytoplasm of the parasite, and the digestive
vacuole. The red blood cell and parasite cytoplasm are very similar in pH, about 7.1. At
this pH, CQ has a +1 charge and is able to freely move through the cell membranes all
the way into the digestive vacuole (Chinappi, 2010). The pH of the digestive vacuole is
about 5, which makes CQ have a 2+ charge. Because of this large pH difference and
3

formation of the doubly charged species, CQ is able to accumulate in the DV much
higher than in the cytoplasm (Kuhn, 2007). In the digestive vacuole, CQ interacts with
heme, preventing the formation of hemozoin, eventually killing the parasite (Roepe,
2009). The exact method of inhibition by CQ is not known, but it is believed that CQ
might affect the pH of the DV, therefore affecting the heme polymerization. Another
idea is that CQ binds directly to heme, preventing development of a crystal (Roepe,
2009).

Chloroquine (CQ)
Figure 2: The structure of CQ.

Despite the effectiveness of CQ, there is increasing worldwide resistance to CQ
as well as to many other antimalarial drugs. The digestive vacuole of the CQ-sensitive
and -resistant P. falciparum has a membrane transporter called the P. falciparum
chloroquine resistance transporter (PfCRT), which is partly responsible for the increasing
resistance to chloroquine. Resistant parasites have been found to have a mutated
version of the pfcrt gene, causing mutations in the protein sequence that allows the
parasite to move CQ out of the digestive vacuole. With CQ at a reduced DV
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concentration, hemozoin is once again formed allowing the parasite to survive
(Chinappi, 2010).
CQ resistance isn’t caused by just one mutation of a nucleic acid in the pfcrt
gene, but by many mutations. Outlined in Table 1 are the various strains of CQ-resistant
P. falciparum and the mutations of amino acids that lead to resistance. It is important
to note that there isn’t just one strain of CQ-resistant malaria that spread across the
world, but rather resistance to CQ developed independently in different parts of the
world, with different types of mutations leading to the resistance. A common mutation
in all the strains listed in the table is a change from lysine at the 76 position to
threonine. The CQ-sensitive strain labeled 106/1 has many of the same mutations as
the resistant strands, except it doesn’t have the mutation at the 76 position. This
indicates that mutating the positively charged lysine to an uncharged threonine is a key
mutation in resistance to CQ (Wellems, 2001).
PfCRT position and encoded amino acid
Parasite type and origin

72 74 75 76 97 220 271 326 356 371

CQ-sensitive
Wild type

C

M

N

K

H

A

Q

N

I

R

106/1

C

I

E

K

H

S

E

S

I

I

SE Asia and Africa, type E1a

C

I

E

T

H

S

E

S

T

I

SE Asia and Africa, type E1b

C

I

E

T

H

S

E

S

I

I

Papua New Guinea, type P1

S

M

N

T

H

S

Q

D

L

R

South America, type W1a

S

M

N

T

H

S

Q

D

L

R

South America, type W1b

C

M

N

T

S

Q

D

L

R

South America, type W2

C

M

E

T

H
Q

S

Q

N

I

T

CQ-resistant

Table 1: Comparison of key amino acids in CQ-sensitive and CQ-resistant strains of P. falciparum as
well as where the resistant strains originated.
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The increasing resistance of P. falciparum to CQ, leads to a need for more
potent, cost effective drugs that are active against this parasite. A new drug, PL69, has
been synthesized that is a “reversed chloroquine” (RCQ), which combines chloroquine
with a reversal agent (Figure 3). Reversal agents are molecules that reverse resistance
to drugs; in this case, reversing resistance to chloroquine. Reversal agents can be taken
with a drug as a cocktail or can be combined with the drug molecule to make a new
drug, which is what was done in the case of PL69. The reversal agent on PL69 reduces
the efflux of the chloroquine-like drug from the digestive vacuole, reversing the
parasite’s resistance (Burgess, 2010). The IC50 values of CQ and PL69 for a CQ-sensitive
strain and a CQ-resistant strain are listed in Table 2. These IC50 values refer to the
concentration of drug needed to inhibit growth of the Plasmodium by 50%. PL69 has a
lower IC50 than CQ against the sensitive strain as well as has a very low IC50 against the
resistant strain, showing that PL69 reverses CQ resistance (Andrews, 2010).

CQ-like portion

Reversal agent portion

Figure 3: Structure of PL69, a reversed chloroquine, indicating the CQ-like
and reversal agent portions of the molecule

6

IC50 (nM)
Compound

D6 (sensitive)

Dd2 (resistant)

CQ

7

102

PL69

1.6

1.8

Table 2: IC50 values of CQ and PL69 for a CQ-sensitive and a CQ-resistant strain of
P. falciparum (Andrews, 2010).

As drugs are developed, their metabolism products need to be identified quickly
and early in the drug discovery process. There are multiple reasons as to why it is
important to elucidate drug metabolism products, including to determine toxicity,
efficacy, and pharmacokinetics of the metabolites. There are three phases in drug
metabolism, commonly listed as phase I, phase II, and phase III. Phase I is mostly done
by the cytochromes P450 and makes the substrate more water soluble. This usually
occurs by some sort of oxidation, but can also occur through N-dealkylation, hydrolysis,
demethylation, etc. In phase II, the oxidized substrate is conjugated to a charged
species. Phase II processes include glucuronidation, sulfation, glutathione conjugation,
and methylation. Phase III consists of elimination of the xenobiotic from the body
(Jurva, 2003).
Human phase I drug metabolism takes place mostly in the liver, but also can
occur in the digestive tract. In humans, there are 75 different isozymes of CYP450 with
a large majority of these being embedded in membranes (Danielson, 2002). The liver
has other enzymes involved in metabolism, but 75% of phase I drug metabolism is done
7

by CYP450s. Of those CYPs, almost half of the metabolism is done by just three
isozymes, CYP3A4, 5, and 7. There is a cofactor that is consistent in all CYP450s, which is
iron(III)protoporphyrin IX, or heme (Woggon, 2007). This porphyrin cofactor is the
reactive center of the CYP450s, producing the active species by binding to molecular
oxygen. The general reaction catalyzed by CYP450 is shown in the following equation,
with “SH” signifying substrate:
NAD(P)H + O2 + SH + H+  NAD(P)+ + SOH + H2O
The role of CYP450 in drug metabolism is to activate oxygen, which can then
attack the substrate, introducing more polar functionality, making it more water soluble
(Danielson, 2002). The main reaction of CYP450s that is discussed in literature is
hydroxylation (shown above), but there are many other reactions catalyzed by this
enzyme. These other reactions include, but are not limited to, deamination,
epoxidation, S-, N-, and O-dealkylations, and dehalogenations.
It is not often easy to determine the identity of metabolites, but it is important
to do so. Looking at the pharmacokinetics allows the identification of what CYP is
involved in metabolism to help in determining drug-drug interactions as well as knowing
how fast the drug is degraded. There are multiple methods to examine metabolism,
some easier and cheaper than others. Even though many of the products are the same,
they are produced in various amounts and sometime there are more or less metabolites
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depending on the method. The next section will discuss the most common types of in
vitro metabolism as well as chemical mimics of enzymatic oxidations.

9

Mimicking in vivo Metabolism
There are many new drug candidates being synthesized every day and in order
for the drug to advance in clinical trials, the metabolites need to be identified and any
toxicity made to be evaluated. There are a few ways of identifying metabolites, but the
current methods usually include using hepatocytes or liver microsomes. Microsomes
are vesicle-like structures formed upon homogenization of the liver and differential
high-speed centrifugation. During homogenization and centrifugation, the CYP450
enzymes become very concentrated in these vesicles, making them desirable for
analysis of metabolites (Baranczewski, 2006). Hepatocytes and microsomes give fairly
accurate in vitro depictions of the type of transformations the drug will undergo.
However, there are some downsides to using these methods. Both hepatocytes and
microsomes must be extracted from an organism and kept frozen, leading to a high cost
for every drug incubation. Another downside of using these in vitro methods is that the
enzymes don’t remain active for very long and it is often difficult to obtain enough
product for complete analysis of the metabolites.
In order to minimize costs of examining the metabolites formed, there has been
an increasing amount of research on chemical mimics of CYP450 systems. These mimics
include an electrochemical system using the Fenton reaction, and using
metalloporphyrins to mimic the heme cofactor present in CYP450s. The Fenton reaction
involves using an electrochemical cell to reduce Fe3+ to Fe2+, which then reacts with
10

hydrogen peroxide, generating hydroxyl radicals and Fe3+ (Figure 4). The
electrochemical cell then reduces the iron, regenerating Fe2+ and starting the oxidation
process over. The hydroxyl radicals can add to aromatic rings and double bonds causing
oxidation such as what would be seen with CYP450 (Johansson, 2007).
eFe2+ + H2O2  Fe3+ + OH- + ·OH
Figure 4: The electrochemical Fenton reaction

A study to compare electrochemical oxidation products with those formed in
CYP450 reactions was done by Ulrik Jurva (Jurva, 2003). The results of that study
showed that the products of the electrochemical oxidation were often the same as
those seen in the enzyme catalyzed reactions. The reactions that were found to work by
this method were one-electron oxidations such as N-dealkylation, alcohol oxidation, and
dehydrogenation. Hydrogen atom abstraction reactions had too high of oxidation
potentials, and include reactions such as O-dealkylation and hydroxylation of
unsubstituted aromatic rings. Even though the method using electrochemical oxidation
does not fully mimic the type of oxidations of the CYP450 enzymes, it is a good model to
examine oxidation products to propose the type of products that may be formed by
microsomes or hepatocytes (Jurva, 2003).
Another model system to study drug oxidation involves mimicking part of the
active site of CYP450s, rather than just mimicking their oxidation reactions. The active
site of CYP450 has an iron protoporphyrin IX, which creates active species of oxygen
that cause the oxidation processes. Research is ongoing using metalloporphyrins as
11

mimics of the CYP450 active site, heme. The most useful CYP-mimicking porphyrins are
water soluble metalloporphyrins, which can more closely mimic the environment in
which metabolism occurs, as compared to metalloporphyrins that are only soluble in
organic solvents (Bernadou, 1990). Metalloporphyrins have the same benefits as the
electrochemical systems, as compared to microsomes and hepatocytes, except the
system does not regenerate itself. Research has been done on various types of
metalloporphyrins, including changing the metal ions and attaching different groups to
the porphyrins (Johansson, 2007).
There are quite a few instances showing that metalloporphyrin oxidations can
mimic CYP reactions when added in conjunction with an oxygen donating compound,
such as hydrogen peroxide. A study done by J. Bernadou compared the activity of
various metalloporphyrins to horse radish peroxidase (HRP), which has a heme group in
the active site (Bernadou, 1990). Four metalloporphyrins were used: iron(III) and
manganese (III) tetrasodium meso-tetrakis(p-sulfonatophenyl)porphyrin [Fe(III)TPPS
(Figure 5) and Mn(III)TPPS, respectively], and iron(III) and manganese(III) tetraacetate
meso-tetrakis(4-N-methylpyridiniumyl)porphyrin [Fe(III)TMPyP and Mn(III)TMPyp,
respectively]. Oxidation of acetaminophen by these four metalloporphyrins and HRP
were examined, because the oxidation product of acetaminophen is known. The
metalloporphyrins and HRP all produced the desired metabolite, N-acetyl-pbenzoquinone-imine (NAPQI) with varying rates and yields. Both Fe(III)TPPS and HRP
had initial turnover rates that were too fast to be measured. The amount of NAPQI
12

produced by Fe(III)TPPS (88% yield) was higher than the other metalloporphyrins, as
well as higher than HRP (40-50% yield). The other metalloporphyrins transformed
between 20 and 50% of acetaminophen to NAPQI, which at the high range is
comparable to the amount of product produced by HRP (Bernadou, 1990). This study is
a good indicator of how metalloporphyrins can be mimics of an oxidizing enzyme.

Figure 5: Structure of iron (III) tetrasodium meso-tetrakis(p-sulfonatophenyl)porphyrin.

Another study compared the products produced by oxidizing metoprolol with
human and rat liver microsomes, the electrochemical Fenton reaction, and a
metalloporphyrin system using Fe(III)TPPS (Figure 5) (Johansson, 2007). The products
were examined using liquid chromatography coupled with a mass spectrometer (LCMS).
Looking at the LC chromatograms, there were seven products produced by rat liver
microsomes, and four produced by human liver microsomes. The electrochemical
13

Fenton reaction produced five of the same products as the rat microsomes and the
porphine system produced six of the seven products. The products were also analyzed
by mass spectrometry in order to be sure the peaks seen in the chromatograms were
the same. Between each method, there was variation in the amounts of products
produced, but both methods formed the major metabolites seen in the microsome
systems. This research group analyzed the oxidation products of other drugs to
compare the products of each system, as well as to determine the mimic system that
best executed each type of reaction, the results of which are shown in Table 3. The
porphine system was recommended as a mimic for many of the enzymatic oxidations,
including N-dealkylation, alcohol oxidation, and aliphatic hydroxylation (Johansson,
2007).
Enzymatic Oxidation

Recommended System

Aliphatic hydroxylation

EC-Fenton or porphine

Benzylic hydroxylation

EC-Fenton or porphine

Aromatic hydroxylation

EC-Fenton or porphine

N-dealkylation

EC-Fenton or porphine

N-oxidation

Porphine

O-dealkylation

Porphine

Alcohol oxidation

Porphine

Aldehyde oxidation

Porphine

Deydrogenation

EC-Fenton or porphine

Table 3: The recommended systems for mimicking various enzymatic oxidations (Johansson, 2007).
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While the electrochemical system seems effectively to mimic enzymatic
oxidation, there is more equipment needed to use it. The easier use of
metalloporphyrins and more readily available equipment led to the use of Fe(III)TPPS for
the research done in this thesis. Rat liver microsomes were also used to compare the
products of metabolism to the oxidative products from the porphine system.

Figure 6: structure of PL69 - a reversed chloroquine

Based on the literature of the metalloporphyrins oxidations, it was hypothesized
that there could be N-dealkylation at the amine linkages in PL69 (Figure 6), aromatic
hydroxylation, or hydroxylation on the aliphatic carbon chain or piperidine. A metabolic
study was done on PL69 by WuXi AppTec, but the only type of analysis done on the
products was LC-MS. In order to fully understand the products formed, NMR analysis
needed to be done, which was the main method of elucidation used in this thesis. The
incubations done with both methods had to be done in sufficiently large quantities in
order to obtain enough product formation to be analyzed by NMR.
The metabolism of PL69 in human, rat, and liver microsomes was analyzed
through mass spectrometry by WuXi AppTec, a bio analytical company based in China.
Figure 7 shows the proposed structures for the metabolites produced in the highest
15

amounts. The percent formation in human liver microsomes is listed after the
molecular weights. Table 4 lists the percent formation of each metabolite in rat,
monkey, and human liver microsomes. Many of the proposed metabolism products are
results of N-dealkylation and/or oxygenation. M1 and M3 were produced in the highest
amounts in the human microsomes, 14.26% and 21.30%, respectively, as measured by
LCMS. M1 and M3 were also produced in high amounts in the rat and monkey
microsomes (Table 4). The relative abundance was calculated by the areas of the parent
and metabolite peaks on the mass spectrum. There were some metabolites not
produced in the human microsomes that were produced in the either the monkey or rat
microsomes, but many of the high yield metabolites were produced with the
microsomes of all three species. Mass spectrometry provides an accurate mass and
general picture of what the molecule might look like based on the mass, but without
other structural analysis, mostly by NMR, the complete structures will not be known.
Relative Abundance (%)
Metabolite

human liver microsomes

monkey liver
microsomes

rat liver microsomes

M1

14.26

7.18

15.13

M2

8.20

3.26

15.97

M3

21.30

36.20

18.95

M4

n/a

1.22

n/a

M5

8.40

5.05

0.83

M6

5.80

3.68

1.85

M7

n/a

1.91

n/a

M8

6.48

10.48

4.25

M9

0.85

n/a

4.58

M10

0.58

n/a

n/a

Table 4: Percentage of metabolites found from incubation with rat, monkey, and human liver
microsomes. This data was determined by WuXi AppTec. Structures of these metabolites are in
Figure 7.
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Figure 7: The proposed metabolism of PL69 using human liver microsomes. The metabolite
molecular weight and the percentage formed are listed under the structures.
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Methods
The antimalarial compound, PL69 (Figure 8), was analyzed using microsomes and
iron(III)meso-tetrakis(p-sulfonatophenyl)porphyrin (Fe(III)TPPS) to examine the
oxidations that mimic in vivo metabolic reactions. The resulting products were
separated and analyzed using HPLC, NMR, and mass spectrometry.
Microsomal Incubations -Rat liver microsomes and an NADPH regenerating system were
purchased from BD Biosciences. The rat liver microsomes were harvested from male
Sprague-Dawley rats and were in a concentration of 20 mg/mL in a 250 mM sucrose
solution. The NADPH regenerating system consisted of two solutions, Solution A (26
mM NADP+, 66 mM glucose-6-phosphate, and 66 mM MgCl2 in H2O) and Solution B (40
U/mL glucose-6-phosphate dehydrogenase in 5 mM sodium citrate). The method for
doing the microsomal incubations was adapted from the procedure provided by BD
Biosciences upon purchase of the microsomes.
There was a small scale incubation (0.5 mL total) of PL69 with the microsomes and then
the method was scaled up. The large scale method consisted of the following final
concentrations (final volume of 5 mL): 50 uM PL69, 100 mM phosphate buffer (pH 7.4),
0.5 mg/mL rat liver microsomes, 20x dilution of NADPH solution A, and 100x dilution of
NADPH solution B. Everything but the microsomes were added, which were added after
the solution was in a 37oC water bath for 5 minutes. The solution was then incubated
for 60 minutes in the 37oC water bath. After 60 minutes, the solution was then put on
18

ice, and ice cold acetonitrile was added to halt the enzyme activity and precipitate the
proteins. The solution was then centrifuged and the supernatant collected. The
products were extracted by raising the pH to above 10 and extracting with
dichloromethane (DCM).
Porphyrin incubations – Porphyrin incubations were done on both PL69 and PL16 (Figure
8), because PL16 is known from the microsomal incubations as well as other studies to
be a metabolite of PL69. Thus, incubating PL16 would show whether further
metabolism would occur.

Figure 8: Structures of PL69 and PL16, two RCQs.
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PL69 porphyrin incubations - Two PL69 incubations were conducted at varying
incubation lengths, 30 or 60 minutes. The incubation solution before adding the
hydrogen peroxide consisted of 70 mM formic acid, 7.8% acetonitrile, 4.5 mg/mL PL69,
and 1.5 mg/mL Fe(III)TPPS for the 60 minute incubation, and 6.6 mg/mL PL69 and 1.2
mg/mL Fe(III)TPPS for the 30 minute incubation, all in a total volume of 5 mL. This
solution was placed in a foil wrapped Erlenmeyer flask, put in a 50oC water bath, and
allowed to equilibrate for a few minutes. Hydrogen peroxide (30%) was added to
initiate the reaction making the solution, initially, 3% hydrogen peroxide. The solution
was incubated for 30 or 60 minutes with intermittent stirring. Sodium hydroxide (100
mM) was added to bring the solution to above pH 10. Dichloromethane (DCM) was
used to extract the products from the solution. The DCM was removed using a rotary
evaporator. A drying agent as not used with the DCM because the products were run
through the HPLC for purification and didn’t need to be completely pure at this point.
PL16 porphyrin incubation - The incubation solution before adding the hydrogen
peroxide consisted of 70 mM formic acid, 7.8% acetonitrile, 5.6 mg/mL PL16, and 1.8
mg/mL Fe(III)TPPS in distilled water. This solution was placed in a foil wrapped
Erlenmeyer flask, put in a 50oC water bath, and allowed to equilibrate for a few minutes.
Hydrogen peroxide (30%) was added and the solution was incubated for 45 minutes
with intermittent stirring. The same method of extraction as used for the PL69
porphyrin incubations was used for the PL16 incubations.
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High performance liquid chromatography - HPLC was used to do initial analysis of the
incubation solutions as well as to separate the products. The HPLC used was a dual
pump Varian Prostar 210 solvent delivery module model, and the processing software
was Galaxie Chromatography. Attached was a Varian Prostar 325 dual wavelength
UV/VIS detector, set at 254 and 280 nm. A Varian Prostar 701 fraction collector was
attached to the HPLC system in order to collect the fractions of interest. The solvents
used were HPLC grade water and acetonitrile, both with 0.1% formic acid. The column
used was a reversed phase Ascentis C18, 150x4.6mm, 5um. The gradient used for
analysis is outlined in Table 5.
Time (min)

%A

%B

Flow rate (mL/min)

0

95

5

1.25

2

95

5

1.25

10

35

65

1.25

Table 5: Elution parameters of the HPLC analyses and separations. A= water with 0.1% formic acid. B=
acetonitrile with 0.1% formic acid. For separating the products, the gradient was modified depending on
how close the peaks were together and where they eluted, but the column and solvents remained the
same. The fraction collector was set to collect each fraction for 30 seconds.

Analysis
HPLC- Purity of the fractions obtained from the HPLC were analyzed using the HPLC.
The retention times were also examined to determine the peaks that were the same
products.
NMR Spectroscopy- Structural analysis was done using a Bruker 400 MHz nuclear
magnetic resonance (NMR) spectrometer, a Bruker 600 MHz NMR was also used in
some experiments.
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Mass Spectrometry- Mass analysis was done using the ThermoElectron LTQ-Orbitrap
Discovery high resolution mass spectrometer at the Portland State University
BioAnalytical Mass Spectrometry Facility.
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Results
There were many products formed in both the microsome and porphyrin
methods used. This was evidenced by the many peaks present when the sample was
run on the HPLC as well as multiple species in NMR spectra and mass spectra. There
weren’t high enough quantities of all of the products to collect and obtain good spectra
on the NMR, but the 9 products produced with the highest yields were analyzed by NMR
spectroscopy and mass spectrometry. These nine proposed oxidation products are in
Figure 9 on the next page. The elucidation of the each individual product is explained
on the following pages. Some of the products were not fully elucidated due to low
yields or loss during purification, but the base structure for each product was
determined.
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Figure 9: Oxidation products of PL69 and PL16 obtained by incubation with rat liver microsomes or a
porphyrin oxidation system. Products were elucidated by NMR and mass spectrometry.
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Product 1

Figure 10: Proposed structure of product 1 (P1).

Product 1 (P1) was present in all of the porphyrin incubations using both PL69
and PL16. P1 was produced in three incubations, and the 1H NMR spectrum as
compared to PL69 is shown in Figure 11. The top spectrum is PL69 and the arrows point
to the corresponding quinoline peaks in the bottom spectra. As seen from these 1H
NMR spectra, all five of the quinoline peaks are present in P1 with fairly similar chemical
shifts to each other as well as to the PL69 quinoline peaks. There were no peaks in the
aliphatic region of this product, indicating that the product was composed of hydrogens
solely from the quinoline ring. From the NMR data, it was hypothesized that P1 was 4amino-7-chloroquinoline. Figure 13 lists the average chemical shifts of the P1 obtained
from the three incubations as compared to 4-amino-7-chloroquinoline. The average
was taken because this product was obtained a few times and in each NMR spectrum
had a slightly different shift. The chemical shifts and the splitting of the peaks are very
similar to actual 4-amino-7-chloroquinoline (Figure 12 and 13).
Mass spectrometry data was collected for product 1 in each of the three
incubations to confirm the identity, which is listed in table 6. The theoretical exact mass
for the chemical formula with one hydrogen added from using positive ESI (C9H8ClN2)
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was 179.03760. The product 1 from the three incubations had m/z values very close to
the theoretical exact mass, with acceptable ppm differences. Therefore, it was
confirmed that product 1 is 4-amino-7-chloroquinoline.

a

c

e

PL69

d

b

PL69
MeOD

P1
MeOD

Figure 11: NMR spectra of PL69 in comparison with product 1, 4-amino-7-chloroquinoline. The
quinoline hydrogen peaks of PL69 are indicated with letters corresponding to the structure of PL69.
The arrows show the corresponding hydrogens in the quinoline ring.
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4-amino-7-chloroquinoline
MeOD

P1
MeOD

Figure 12: 1H NMR spectra of 4-amino-7-chloroquinoline and Product 1. The peaks of P1 are shifted
fairly similar to 4-amino-7-chloroquinoline. There are two peaks at 7.61 and 7.68 ppm that are
impurities that are also present in other samples.

Average

Theoretical

shift (ppm)

shift (ppm)

a

8.25

b

Position

Integration

Multiplicity

8.27

1

d

6.72

6.61

1

d

c

8.15

8.07

1

d

d

7.54

7.39

1

dd

e

7.82

7.77

1

d

Figure 13: 1H NMR assignments of product 1 as compared to 4-amino-7-chloroquinoline. The
structure on the left shows the assignment of the hydrogens.

Source of Product
theoretical C9H8ClN2
PL69 with Fe(III)TPPS (1)
PL69 with Fe(III)TPPS (2)
PL16 with Fe(III)TPPS

Obtained m/z
179.03760
179.03702
179.03619
179.03687

Δppm
n/a
3.2451
7.8810
4.0829

Table 6: The exact mass of C9H8ClN2 is listed as well as the m/z values obtained for product 1 that was
collected from the three different incubations. The Δppm represents the difference between the
obtained product m/z and the theoretical exact mass, divided by the theoretical mass.
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Product 2

Figure 14: Proposed structure of product 2 (P2).

Product 2 (P2) is actually two products that were determined from the
microsomal incubations. Both have 1H NMR spectra similar to an already known
compound, PL16. The two products will be referred to as P2A and P2B. These products
were the few isolated compounds from the microsomal incubations. Shown in Figure 15
and 16 are the spectra for PL16 (top), P2A (middle), and P2B (bottom). In the aromatic
region, P2A and P2B have slightly different shifts from PL16, but very similar shifts to
each other and the same type of splitting in present. In the aliphatic region (Figure 16),
the same shaped peaks are present, but are at different chemical shifts. The quartet
seen at 4.11 ppm is the methylene peak of ethyl acetate. PL16 and P2A have very
similar shifts for the two triplets and the pentet. P2B, however, has one triplet shifted
from 3.74 ppm to 4.24 ppm and the pentet is shifted from 1.98 ppm to 2.11 ppm. It is
hypothesized that P2A is PL16 and P2B is a molecule similar to PL16, but possibly with a
different electron withdrawing group that causes hydrogen “h” to shift farther
downfield. The shift changes in the aromatic region could possibly be accounted for by
pH differences between the samples. The aromatic protons seem to be highly
influenced by slight pH changes.
28

PL16
PL16
MeOD

a

c

e

d

b

P2A
MeOD

P2B
MeOD

Figure 15: The aromatic regions of PL16, P2A, and P2B. Notice the similar chemical shifts. The
structure of PL16 is above the spectra with labeled hydrogens.
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h

f

g

PL16
MeO
D

P2A
MeO
D

P2B
MeOD

Figure 16: The aliphatic regions of PL16, P2A, and P2B.
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Product 3

Figure 17: Proposed structure of product 3 (P3).

Product 3 (P3) was determined to consist of a piperidine, but the exact structure
is not known. The 1H NMR spectrum of P3 in D2O and MeOD is shown in the bottom
two spectra of Figure 18 and the top two spectra are PL69 in CDCl3 and MeOD. The
piperidine peaks of PL69 are indicated in the structure of PL69 and the 1H NMR peaks of
those hydrogens are labeled on spectra. The relationships of the piperidine peaks of
PL69 to the peaks of P3 are indicated by arrows. After obtaining spectra for P3 in D2O
and MeOD, the four peaks of the hydrogens in the 2- and 3-positions were easily
identified. A 1H NMR peak for the single hydrogen in the 4-position has not yet been
identified for P3. During one of the many rotoevaporations and dryings to remove extra
solvent, P3 was lost from the round bottom flask in which it was stored. No further
NMR analyses were able to be done in P3 besides 1H NMR spectroscopy and COSY, and,
unfortunately, a mass spectrum was not obtained for this product.
In order to attempt to further elucidate the structure of P3 after having lost the
product, the 1H NMR spectrum of P3 was compared with two substituted piperidines, 4hydroxypiperidine and 4-aminopiperidine (Figure 19). The 1H NMR spectra of these two
piperidines didn’t match the spectra obtained for P3. The splitting observed in the three
compounds were similar, but the chemical shifts were very different. Both 431

aminopiperidine and 4-hydroxypiperidine had well resolved peaks for the hydrogen at
the 4 position, which is not present in the spectra for P3. The peaks had much different
shifts as well. For the time being, the complete structure of P3 will remain unknown,
though, it is probable there is a piperidine group.

e
a&b
c&d

a

PL69
CDCl3

e

c b

d

PL69
MeOD

Product 3
D2O

Product 3
MeOD
a

c

b

d

Figure 18: The structure of PL69 with the piperidine assignments. The spectra shows the 1H NMRs of
PL69 and P3 in different solvents as well as assignments of the peaks with respect to PL69.
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Product 3
MeOD
PL69
Product 3
D2O
PL69
4-aminopiperidine
D2O

4-hydroxypiperidine
D2O

Figure 19: Comparison of 1H NMRs of P3 with 4-hydroxypiperidine and 4-aminopiperidine, the
structures of which are shown under the spectra.

Position
a
b
c
d
e

Observed
shift (ppm)
3.57
2.30
3.13
1.87
3.52?

Integration Multiplicity
1
1
1
1
?

dd
dd
td
qd
?

Figure 20: Structure of P3 with letter assignments correlating to the 1H NMR shifts in the table.
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Product 4

Figure 21: Proposed structure of product 4 (P4).

Product 4 (P4) was present in all of the PL69 incubations with Fe(III)TPPS and was
present in large enough quantities to make it easy to collect 1H NMR data with good
signal to noise ratio (S/N). Upon collecting this product, running a 1H NMR spectrum,
and comparing the 1H NMR spectrum of PL69, it was thought that P4 was probably some
sort of pyridine. However, the chemical shifts of this product were very different than
the shifts of the pyridine in PL69; some of the peaks were shifted farther downfield than
they had been in PL69 (Figure 22). The hydrogen at the 2-position of the pyridine
shifted from 7.51 ppm in PL69 to 8.11 ppm inP4, indicating that a more electronegative
group had been added near that hydrogen. It was originally thought that this product
was picolinic acid, which is pyridine with a carboxyl group attached at the 2-position.
Mass spectrometry data was obtained for P4 giving a mass (m/z=185.07109) that
was much larger than what would be expected for picolinic acid (exact mass=123.03203
amu). To get an m/z of 185.07109 amu, there needed to be two connected pyridine
rings. Based on the mass, the chemical formula of M+1 was determined to be C11H9N2O.
The identity of P4 was postulated to be di(2-pyridyl) ketone. The ppm differences
obtained from the P4 are very low and within a reasonable difference (Table 7).
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The carbonyl group attaching the two pyridyl rings caused the hydrogen at the 2position to shift drastically downfield and also shifted the other hydrogens slightly
farther downfield. A 1H NMR spectrum obtained for known di(2-pyridyl) ketone in
chloroform was compared to a sample of P4 in chloroform to ensure the structure was
elucidated correctly. Those 1H NMR spectra are shown in Figure 23 and listed in Figure
24. With the combination of 1H NMR spectra, mass spec, and comparison to a known
structure, the identity of P4 was determined to be di(2-pyridyl) ketone.

PL69
a

c

d

b

PL69
MeOD
From PL69 w/Fe(III)TPPS (1)
MeOD
30 min inc
From PL69 w/Fe(III)TPPS (2)
MeOD
15+30 min inc
From PL69 w/Fe(III)TPPS (3)
MeOD
1 hr inc

Figure 22: The top 1H NMR spectrum is PL69 and the bottom three spectra are P4 from three
different incubations. Notice the drastic chemical shift changes of some of the pyridine peaks as
compared to those of PL69.
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Source of Product
theoretical C11H9N2O
P4 [Fe(III)TPPS (30min)]
P4 [Fe(III)TPPS (15+30min)]
P4 [Fe(III)TPPS (1hr)]

Obtained m/z
185.07149
185.07133
185.07028
185.07108

Δppm
n/a
0.86453
6.4861
2.1916

Table 7: Mass spectra data obtained for P4 from three different incubations. The top row, C11H9N2O,
is the theoretical exact mass of P4+H, which would be seen in the positive mode mass spectrum.

Di(2-pyridyl) ketone
MeOD

P4
MeOD

Figure 23: The top 1H NMR spectrum is di(2-pyridyl) ketone and the bottom spectrum is P4 obtained
from the 30 minute PL69 incubation with Fe(III)TPPS. The chemical shifts are basically identical,
indicating the identity of P4. There are two impurity peaks at 7.53 and 7.71 ppm. The identity has
not been elucidated, but they are present in other sample spectra so they were determined to be
impurities.

Position
a
b
c
d

Observed
shift (ppm)
8.77
7.50
7.91
8.11

Theoretical
shift (ppm)
8.76
7.49
7.90
8.10

Integration Multiplicity
1
1
1
1

dt
ddd
ddd
dt

Figure 24: The chemical shifts of P4 (observed shift) as compared with di(2-pyridyl) ketone
(theoretical shift). The integration and multiplicity of the peaks are also listed and correlate with
those of di(2-pyridyl) ketone.
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Product 5

Figure 25: Proposed structure of product 5 (P5).

Product 5 (P5) is similar to M9 seen in the incubations done by WuXi AppTec,
except M9 has a hydroxyl at the 4-position of the piperidine rather than an amine. This
product was not isolated during the initial porphyrin incubations, but was isolated in two
of the more recent porphyrin incubations. The 1H NMR spectrum of P5 is similar to that
seen for PL69, except the pyridyl peaks were missing from the aromatic region (Figure 26
and 27). The mass spectrum (Figure 28) obtained for P5 had an M+1 of 319.16736 amu,
with a difference of only 5 ppm from the theoretical mass of C17H24N4Cl (319.16895 amu).
Based on the presence of the same peaks in the aromatic and aliphatic region as PL69 as
well as factoring in the mass, the P5 was determined to be N-(3-(4-aminopiperidin-1yl)propyl)-7-chloroquinolin-4-amine.
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a

c

e

d

b

PL69
MeOD

Product 5
MeOD

Figure 26: Comparison of 1H NMR spectra of PL69 (top) and P5 (bottom). The same quinoline peaks
are present in P5 as in PL69.

f

i

hm

jkm

l

PL69
MeOD

Product 5
MeOD

Figure 27: Comparison of the aliphatic region of PL69 (top) and P5 (bottom). The same peaks are
present in P5, but slightly shifted compared to PL69.
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15 min 7-8 #1 RT: 0.00 AV: 1 NL: 1.92E6
T: FTMS + p ESI Full ms [50.00-2000.00]
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Relative Abundance
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65
60
55
50
45
40

322.16745

35

322.16745

30
25
20

413.26453
413.26453

15

387.14639
387.14639

10
292.14343

5

270.97693

238.31831 248.09399

0
230

240

250

260

270

280.12012

280

331.09668

301.14008 309.20245
290

300

310

347.16217
320
m/z

330

340

355.06851

350

390.15311

371.09976

408.30597
360

370

380

390

400

410

m/z

Figure 28: Mass spectrum of P5.
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Product 6

Figure 29: Proposed structure of product 6 (P6).

Product 6 (P6) proved to be a tricky compound to elucidate. Proton NMR
spectra as well mass spectra have been obtained for P6, but the puzzle of the complete
structure has not been determined. The 1H NMR spectrum for this product in MeOD
gave five peaks in the aromatic region (Figure 30) and no other peaks. By looking at the
chemical shifts of P6 in comparison to PL69, P6 was determined to contain at least one
pyridine ring. To try to see any exchanging protons, P6 was run on the NMR in
deuterated dimethyl sulfoxide (DMSO-d6), which gave very broad peaks. Sodium
deuteroxide (NaOD) was added to the DMSO-d6 sample to try to get sharper peaks,
even though adding NaOD introduced water to the sample, removing the exchanging
proton peaks. Adding NaOD sharpened up the peaks quite a bit, but also started to
oxidize the sample. Every 1H NMR spectra obtained after adding NaOD made the P6
peaks smaller and some other peaks larger, including peaks corresponding to P4, di(2pyridyl) ketone (Figure 30). There seems to be oxidation of P6 to other products besides
just P4, as well.
A mass spectrum was obtained for P6 which gave an m/z in the positive mode of
169.07507 amu, corresponding to a chemical formula of C11H9N2 (Figure 32). The ppm
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difference between the m/z and the exact mass of C11H9N2 is 9 ppm. This formula
corresponds to the actual m/z, rather than the M+1, because there was not a structure
that could be identified, that made sense, for a formula of C11H8N2. The m/z obtained
from the mass spectrum led to the belief that P6 has two pyridine rings. Multiple
structures were examined in order to try to get a product with just one pyridine ring,
but those structures always added in more hydrogens that weren’t present in the 1H
NMR spectrum. It is probable that the molecule fragmented upon entering the mass
spectrometer giving a structure shown in Figure 31. This structure fits with the mass
obtained, but is most likely just a fragment of the actual molecule of P6. One
explanation could be a hydroxyl group attached to the carbon linking the two pyridyl
rings which broke off upon entering the MS. Adding NaOD to the NMR sample would
have neutralized the acid and added hydroxide ions that could oxidize the molecule.

Product 6
MeOD

Product 6
DMSO+NaOD

Product 4
MeOD

Figure 30: The top spectrum is P6 in deuterated methanol. The middle spectrum is P6 in DMSO with
NaOD, a few days after adding NaOD. The bottom spectrum is P4, which seems to be present in the
middle spectrum.
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Figure 31: Possible explanation of P6 fragment measured by the MS. The positive charge could be
stabilized by the aromatic rings.

combo 14-18 #1 RT: 0.00 AV: 1 NL: 1.71E7
T: FTMS + p ESI Full ms [50.00-2000.00]
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Figure 32: Mass spectrum of P6
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Product 7

Figure 33: Proposed structure of product 7 (P7).

The full identity of product 7 (P7) has not been fully elucidated, but the pieces of
this product are known. The 1H NMR spectrum of P7 has four peaks in the aromatic
region (Figure 34). The three hydrogens on the ring with the chlorine have similar peaks
as seen in the 1H NMR spectrum of PL69. However, there is only one peak present in
the spectrum to represent the hydrogens on the ring with the nitrogen. Sometimes, the
hydrogen at the 2-position is not seen in the 1H NMR spectrum, depending on solvent,
but the hydrogen at the 3-position would still be seen as a doublet, so it can be assumed
the 2-position hydrogen was present. However, in the case of this product, there is no
hydrogen in the area of the hydrogen at the 3-position, but there was a singlet slightly
up field from where the hydrogen at the 2-position usually is, leading to the belief that
there was a substitution at the 3-position. The j-values calculated for the spectrum of P7
in the aromatic region were similar to those of PL16, which lead to the peak
assignments. The aliphatic peaks of P7 correspond to those seen in the aliphatic region
of PL16 (Figure 35).
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There were three peaks seen in the aliphatic region that correlated to the three
carbon chain attached to the chloroquinoline ring. There didn’t seem to be any other
hydrogens attached to carbons present in the 1H NMR spectrum. The identity of the “R”
group at position three of the ring was not elucidated. The product was, unfortunately,
lost before obtaining a mass spectrum.

PL16

a

e c

d

PL69

b

PL69
CDCl3

PL16
MeOD

Product 7
CDCl3

?

Figure 34: The aromatic region of P7 as compared to PL16 (top spectrum). There is a loss of the
doublet at 6.5 ppm and the doublet at 8.35 ppm, but there is a singlet at 8.1 ppm.
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f

g

h

PL69
CDCl3

PL16
MeOD

Product 7
CDCl3

Figure 35: The aliphatic region of P7 as compared to PL16 (top spectrum). The P7 peak peak at 3.64 is
a quartet because the solvent is CDCl3 and the hydrogens of that peak are seeing the –NH attached to
the quinoline ring. The triplet at 2.54 is considered an impurity because it does not integrate with the
other peaks. It could possibly be from another product in the sample.
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Product 8

Figure 36: Proposed structure of product 8 (P8).

Product 8 (P8) was only analyzed by mass spectrometry, there was not enough
to obtain a 1H NMR spectrum. It was obtained in a pure form, but was present in the
mass spectrum of some of the other products, including P5. The structures resembles
M9 from the metabolism of PL69 completed by WuXi AppTech (Figure 7) with a carbonyl
added in place of two hydrogens. The ppm difference between the m/z and the
C17H21N3O2Cl (M+1) is just 5 ppm, which means this formula is probably correct. The full
structure cannot be known without NMR data, but the structure above is a probable
structure based on the mass spec data.
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Product 9

Figure 37: Proposed structure of product 9 (P9).

Product 9 (P9) has a theoretical structure similar to P5, except with an added
carbonyl in place of a methylene group. There was not enough of this product to obtain
a well resolved 1H NMR spectrum, so it was only analyzed by MS. This type of structure
would probably make the piperidine ring open and an aldehyde form, which is one of
the few ways a methylene group can be removed without breaking the molecule.
Another possible structure is formation of an ether at the 2- or 3-position of the
piperidine. Possible structures are on the next page in Figure 38. The exact mass of
M+1 is 321.14821 amu, which is a ppm difference of 6 ppm compared to the m/z
obtained, 321.14639 amu.
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Figure 38: Possible structures for P9 to fit the chemical formula C11H21N4OCl.
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Discussion
Oxidation of a reversed chloroquine, PL69, with Fe(III)TPPS allowed for analysis
of oxidation products that are similar to the products obtained with in vitro metabolism
methods. It was hypothesized the products of the porphyrin oxidations would be
similar to those of in vitro methods, but the degree of similarity for PL69 was not known.
The results discussed in this thesis show that, although some of the products of the
porphyrin oxidations were slightly different than those found in the metabolism with
microsomes, they provided a reasonable starting point for metabolism analysis. The
most prominent reaction that occurred was N-dealkylation, but hydroxylation and
oxidation were also seen.
Looking at the metabolite structures proposed by WuXi AppTec, comparisons
can be made between the structures determined with Fe(III)TPPS and the structures
determined with the rat, monkey, and human liver microsomes. Shown in Figure 40 (at
the end of this section) are the structures of the metabolites formed by microsomes
(red), as determined by WuXi AppTec, and the structures determined from the
porphyrin oxidations (blue). When comparing side by side, many similarities are seen in
the products of the microsome and porphyrin incubations. The microsomal incubations
by WuXi AppTech included more dealkylations with addition of oxygen (hydroxyl or
carbonyl), than what was seen with the porphyrin oxidations. This could possibly be due
to higher oxidizing capabilities of CYP450s. P1 and P5 were all formed in the porphyrin
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incubations, as well as the microsomal incubations by WuXi AppTech. This indicates
that the porphyrin method provides products that are similar, if not the same, as what
would be expected in microsomal incubations.
Many oxidation products were produced from reacting PL69 with microsomes
as well as with the iron porphyrin and hydrogen peroxide. Difficulty was encountered
when trying to separate and analyze all of the products from one another, but the main
products obtained were analyzed by NMR spectroscopy and/or mass spectrometry. A
total of ten products were analyzed from incubations with PL69 and PL16 (a known
metabolite of PL69). Unfortunately, some of the products were only analyzed by one
method, either because they were produced in a small amount or the product was lost.
Even though not all of the products were fully elucidated, the suggested structures
provide a good framework for examining oxidation processes of other compounds with
a porphyrin incubation.
There are multiple options for the next steps. First, another microsomal
incubation could be done with PL69 now that there is a better method for separation of
the compounds, in order to compare the products from both methods. Another option
is to use the porphyrin system to examine the oxidation products of other reversed
chloroquines. This same porphyrin system has been used to study one other compound
from the Peyton lab, PL241, by Tess Harris (Figure 39). PL241 has a 4-amino-7chloroquinoline group on both sides of the molecule and produced only four oxidation
products, making it much easier to study than PL69. The products seen in oxidation of
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PL241 followed the same patterns as seen for PL69, with the most prominent reaction
being N-dealkylation. Once the identity of the in vitro or in vivo metabolites are fully
known, the next step would be to examine toxicity as well as efficacy of each of the
metabolites. This would probably include synthesizing the prominent metabolites and
then testing them for activity and toxicity.

Figure 39: Structure of PL241.

Since the porphyrin system produced similar products as what was predicted in
the microsomal incubations, this system could be used to develop an understanding of
possible metabolites for multiple compounds before investing in the more expensive
microsomal incubations. The porphyrin method at least could provide a framework for
understanding what type of metabolism might occur in vivo. The process of separation
and data collection could be improved to provide a much quicker, more efficient
method to examine the products. Overall, using Fe(III)TPPS seemed to be a suitable
mimic of CYP450 in that it produced similar products to those seen with CYP450. This
method should be examined with other reversed chloroquines to determine the
accuracy of oxidation as compared to microsomes and other sources of CYP450.

51

Figure 40: Comparison of the metabolites of PL69 determined by WuXi AppTech (red) with

the products from this research that were elucidated by mimicking metabolism with
microsomes and a metalloporphyrin system (blue). The oxidation products in blue are
similar to the metabolites in red. This shows that using a metalloporphyrin system can
provide a framework for understanding metabolism of a drug.
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Appendix A: NMR spectra of PL69
NMR spectra of PL69 in deuterated methanol
400 NMR
1
H NMR # of scans=16
13
C NMR # of scans=256

Assignment
a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
p
q
r
r'
s
t
t'
u

1

H shift (ppm)
8.34
8.5
7.76
7.77
7.44
8.03
7.53
7.26
6.49
5.24
2.44
2.4
2.95
1.92
3.36
1.95
1.55
1.91

Multiplicity
d
dq
ddd
d
ddd
d
d
ddd
d
s
t
m
d
m
t
m
m
m

Integration
1
2
2
1
1
1
2
2
1
1
2
1
2
2
2
2
2
2

13

C shift (ppm)
162.17
152.71
152.47
149.98
149.63
138.62
136.31
127.63
126.09
124.29
124.06
123.94
118.75
99.59
66.59
57.63
53.87
53.5
53.5
42.89
33.01
33.01
26.13
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Appendix B: NMR spectra of PL16
NMR spectra of PL16 in deuterated methanol
400 NMR
1
H NMR # of scans=16
13
C NMR # of scans=256

Assignment
a
b
c
d
e
f
g
h
i
j
k
l

1

H shift (ppm)

Multiplicity

Integration

13C shift (ppm)

8.34
7.77
7.39
8.05
6.54
3.74
3.47
1.96

d
d
dd
d
d
t
t
p

1
1
1
1
1
2
2
2

152.86
152.22
149.41
136.39
127.41
126.03
124.24
118.71
99.58
60.77
41.26
32.12

Assignment of PL16 NMR chemical shifts
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Appendix C: NMR spectra of oxidation products
NMR spectra of P1 in MeOD
30 minute PL69 porphyrin incubation:
400 NMR
1
H NMR # of scans= 16

62

30 minute PL16 incubation:
400 NMR
1
H NMR # of scans= 256

63

64

65

NMR spectra of P2A and P2B
400 NMR
1
H NMR # of scans= 512
P2A in MeOD:

66

67

P2B in MeOD:

68

69

NMR spectra of P3
In MeOD:
400 NMR
1
H NMR # of scans= 16

70

In D2O:
400 NMR
1
H NMR # of scans= 256

71

Spectra of P4 in MeOD
400 NMR
1
H NMR # of scans=16

72

73

NMR spectra of P5 in MeOD
400 NMR
1
H NMR # of scans= 1024

74

75

NMR spectra of P6
In MeOD:
400 NMR
1
H NMR # of scans= 1024

76

77

In DMSO-d6:
400 NMR
1
H NMR # of scans= 1024

78

In DMSO-d6 with NaOD:
400 NMR
1
H NMR # of scans= 1024

79

NMR spectra of P7 in CDCl3
400 NMR
1
H NMR # of scans= 256
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